DK0936923T3 - Undertrykkelse af TNFalpha og IL-12 ved terapi - Google Patents

Undertrykkelse af TNFalpha og IL-12 ved terapi

Info

Publication number
DK0936923T3
DK0936923T3 DK97912367T DK97912367T DK0936923T3 DK 0936923 T3 DK0936923 T3 DK 0936923T3 DK 97912367 T DK97912367 T DK 97912367T DK 97912367 T DK97912367 T DK 97912367T DK 0936923 T3 DK0936923 T3 DK 0936923T3
Authority
DK
Denmark
Prior art keywords
tnf
tnfalpha
suppression
therapy
disclosed
Prior art date
Application number
DK97912367T
Other languages
Danish (da)
English (en)
Inventor
Marc Feldmann
Anne-Marie Aline Miche Malfait
Debra Maree Butler
Fionula Mary Brennan
Ravinder Nath Maini
Original Assignee
Kennedy Inst Of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Inst Of Rheumatology filed Critical Kennedy Inst Of Rheumatology
Application granted granted Critical
Publication of DK0936923T3 publication Critical patent/DK0936923T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97912367T 1996-11-15 1997-11-17 Undertrykkelse af TNFalpha og IL-12 ved terapi DK0936923T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74997996A 1996-11-15 1996-11-15
PCT/GB1997/003151 WO1998022137A1 (fr) 1996-11-15 1997-11-17 SUPPRESSION DU FNTα ET DE IL-12 EN THERAPIE

Publications (1)

Publication Number Publication Date
DK0936923T3 true DK0936923T3 (da) 2004-04-26

Family

ID=25016019

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97912367T DK0936923T3 (da) 1996-11-15 1997-11-17 Undertrykkelse af TNFalpha og IL-12 ved terapi

Country Status (9)

Country Link
US (1) US20070178099A1 (fr)
EP (1) EP0936923B1 (fr)
AT (1) ATE256476T1 (fr)
AU (1) AU4959997A (fr)
DE (1) DE69726878T2 (fr)
DK (1) DK0936923T3 (fr)
ES (1) ES2213209T3 (fr)
PT (1) PT936923E (fr)
WO (1) WO1998022137A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
AU2612100A (en) * 1999-01-13 2000-08-01 Rockefeller University, The Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
EP2168984B1 (fr) * 1999-03-25 2012-08-29 Abbott GmbH & Co. KG Anticorps humains qui se lient au IL-12 humain et procédé de fabrication
AU768324B2 (en) * 1999-12-14 2003-12-11 Genentech Inc. TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
MXPA02008079A (es) * 2000-02-21 2003-02-27 Applied Research Systems Uso de inhibidores de il-18.
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
EP2316531A1 (fr) 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Apprentissage cognitif amélioré
US20040224316A1 (en) 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US6881407B2 (en) * 2000-08-11 2005-04-19 Ashok Amin Method for treating hepatitis
EP1188438A1 (fr) * 2000-09-15 2002-03-20 Warner-Lambert Company Compositions pharmaceutiques pour la prévention ou le traitement de maladies associées à un excès de production de l' IL-12
EP1199074A1 (fr) * 2000-09-15 2002-04-24 Warner-Lambert Company Composition pharmaceutique pour la prévention ou le traitement de maladies associées à un excès de production d' IL-12
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use
US20030161828A1 (en) * 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1651266B1 (fr) * 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Administration de fragments d'anticorps f(ab')2 anti-tnf-alpha
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
RU2475265C2 (ru) 2007-01-16 2013-02-20 Эбботт Лэборетриз Способы лечения псориаза
KR20100014674A (ko) 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
TW201513883A (zh) 2008-03-18 2015-04-16 Abbvie Inc 治療牛皮癬的方法
KR20110071011A (ko) * 2008-10-20 2011-06-27 아보트 러보러터리즈 Ｉｌ-18에 결합하는 항체 및 이의 정제 방법
RU2520838C2 (ru) * 2008-10-20 2014-06-27 Эббви Инк Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
JP2012506384A (ja) * 2008-10-20 2012-03-15 アボット・ラボラトリーズ Ｉｌ−１２に結合する抗体およびそれを精製する方法
CN104974251A (zh) * 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
MX2012003138A (es) 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Metodos para tratar la psoriasis.
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
US8394593B2 (en) * 2010-02-12 2013-03-12 Trudeau Institute Use of an IL-12 receptor splice variant and molecular assay to quantify expression thereof
US8877212B2 (en) 2011-02-07 2014-11-04 Trudeau Institute Use of an IL12 receptor-beta 1 splice variant to diagnose active tuberculosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
EP1681305A3 (fr) * 1991-03-18 2008-02-27 New York University Anticorps monoclonaux et chimères contre le facteur humain de nécrose de tumeurs
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
JP3616091B2 (ja) * 1992-10-08 2005-02-02 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
US5536657A (en) * 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
EP0759466B1 (fr) * 1995-08-01 2005-12-28 F. Hoffmann-La Roche Ag Récepteurs d'interleukine 12-bêta à faible affinité pour son ligand

Also Published As

Publication number Publication date
DE69726878T2 (de) 2004-10-21
WO1998022137A1 (fr) 1998-05-28
PT936923E (pt) 2004-04-30
EP0936923A1 (fr) 1999-08-25
AU4959997A (en) 1998-06-10
US20070178099A1 (en) 2007-08-02
ATE256476T1 (de) 2004-01-15
ES2213209T3 (es) 2004-08-16
EP0936923B1 (fr) 2003-12-17
DE69726878D1 (de) 2004-01-29

Similar Documents

Publication Publication Date Title
DK0936923T3 (da) Undertrykkelse af TNFalpha og IL-12 ved terapi
DE69125025D1 (de) Verfahren zur homo- oder copolymerisation von ethen
EP0620409A3 (fr) Simulation électro-optique de cible et fond.
HK1022440A1 (en) Combination therapy using a tnf binding protein for treating tnf-mediated diseases
DE69007344D1 (de) Blockcopolymerzusammensetzung.
DE68927671T2 (de) Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
NO901112L (no) Adaptiv terskelholdingsteknikk.
IT8125097A0 (it) Procedimento e dispositivo perl'introduzione di almeno un inserto in fascicoli.
IL118483A0 (en) Methods for inhibiting vascular smooth muscle cell migration
DK0760010T3 (da) Fremgangsmåder til screening for Crohn's sygdom under anvendelse af TNF-mikrosatellit-alleler
DE3852389T2 (de) Rissformungsverhütung in implantierten Prothesen.
DE3878567T2 (de) Vinylmonomer enthaltende haertbare siliconzusammensetzungen.
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
IT8819515A0 (it) Copolimero acrilico idrossilato.
IT8424113A0 (it) Metodo per la preparazione di copolimeri aggraffati per polimerizzazione in emulsione.
GR3021421T3 (en) Compositions for use in a method for treating a human suffering from multiple sclerosis
ZA989036B (en) Methods and compositions for treating rheumatoid arthritis.
EP0642333A4 (fr) Procede et composition pour le traitement de troubles associes a un dysfonctionnement immunologique.
HUP0002304A2 (hu) Állatok májából kivonható fehérjék alkalmazása tumor nekrózis faktor túltermelődéssel járó kóros állapotok kezelésére használható gyógyászati készítmények előállítására
ITMO930022A1 (it) Impianto di smistamento, formazione e allontanamento di pile, di piastrelle ceramiche multiformato.
NO983220D0 (no) Sammensetninger og fremgangsmater for ö administrere Borrelia Burgdorferi-antigener
DE3888452T2 (de) Acrylatcopolymer-Elastomer.
IT9003692A0 (it) Dispositivo per l' assemblaggio di pannelli di mobili in genere.
FR2666473B1 (fr) Procede et appareil pour ameliorer la qualite de la restitution d'une ambiance sonore en stereophonie.
FR2714017B1 (fr) Mat orientable.